CD274 and cancer: Recently, immunotherapy using immune checkpoint antibodies targeting PD‐1 (programmed cell death‐1/PD‐L1 [programmed cell death‐1 ligand]) has been shown to improve outcomes in patients with various malignant tumors.29, 30